Af­ter 12 months of dig­ging, Pfiz­er opts for one of two Voy­ager cap­sids for gene ther­a­py

The path at Voy­ager Ther­a­peu­tics keeps wind­ing, and at the 12-month dead­line, Pfiz­er has elect­ed to on­ly move for­ward with one of two cap­sids out of the pre­clin­i­cal biotech for the Big Phar­ma’s AAV gene ther­a­pies.

Last Oc­to­ber, the Big Phar­ma and biotech linked arms on a deal that gave Pfiz­er the abil­i­ty to hit the gas ped­al on two cap­sids: one for a car­diac tar­get and the oth­er for a rare neu­ro­log­ic dis­ease tar­get.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER